High blood pressure affects about 45% of U.S. adults. In the 1970s, only about 50% of patients were aware of their hypertension. Today, 54% are aware of their high blood pressure, 40% are actively treated and 21% are actively controlled. As such, researchers alert health care providers that the old “silent killer” is alive and well.
Exciting research at the frontier of artificial intelligence and data science in laboratory medicine was presented today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo).
New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
More than two-thirds of people taking blood thinners take direct oral anticoagulants, or DOACs, which are under- or over-prescribed in up to one in eight patients. A new study finds that most prescribing issues for DOACs occur after a provider writes the initial prescription. Researchers say the findings highlight why patients on DOACs need to be monitored consistently.
A head-to-head comparison of six commercially available blood tests for Alzheimer’s disease led by researchers at Washington University School of Medicine in St. Louis reveals that two are accurate enough to replace brain scans and spinal taps in some patients with cognitive impairments.
Chronus Health has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics.
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and information systems, today announced that longtime healthcare executive Dan Zortman has been named the company’s new CEO.
The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today announced the recipients of this year’s Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership, and Meritorious Service Awards. These prestigious accolades will be presented to the winners this November during AMP’s 2024 Annual Meeting & Expo in Vancouver, British Columbia.
As a Fulbright-Fogarty fellow, Katie Farkouh will spend nine months in Accra, Ghana, studying urinary tract infection (UTI) risk and treatment outcomes in children with sickle cell disease.
In a rigorous medical records study covering tens of thousands of patients, Johns Hopkins Medicine researchers conclude that some patients with preoperative anemia have better outcomes if they get iron infusions before surgery rather than standard red blood cell transfusions.
How a person’s immune system responds to a protein called LL-37 may increase risk for developing acute coronary syndrome, but the response may also serve as a potential target for future treatments.
In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
A new study has discovered genetic markers in inflammation that may be related to a second stroke or other major cardiovascular event following a stroke. These findings could help identify drug targets to mitigate stroke-related disability and mortality.
Relapsed B-cell ALL is the leading cause of cancer-related deaths in children and young adults. UniSA research has shown the potential of new microfluidic technology, to improve the CAR T-cell manufacturing process by efficiently removing contaminating cancerous cells and other large white blood cells - potentially leading to greater access and lower costs of treatment.
In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.
A new study in mice hints at the promise of an eventual alternative treatment option for the “wet” version of age-related macular degeneration (AMD).
Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, international phase 2 clinical trial showing a new, curative treatment for sickle cell disease (SCD).
Dr. Zhen Mei, a clinical pathologist, and Dr. Vivian Chang, a pediatric hematologist-oncologist, both at UCLA Health, have been awarded $30,000 from the American Society of Hematology to revise blood cell ranges for people with Duffy-null Associated Neutrophil Count, which is also known as Duffy-negative
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right